Bloomage Biotechnology

Bloomage Biotechnology is a Chinese biotechnology and consumer-beauty company associated with research, development, production, and commercialization of hyaluronic-acid-related ingredients and finished products. Its business spans bioactive raw materials, functional skincare, and medical or healthcare applications, giving it a position across both business-to-business ingredient supply and consumer-facing brands. The company’s best-known consumer brand portfolio includes skincare labels such as Biohyalux, QuadHA, and Medrepair. These brands are positioned around hydration, barrier care, repair, and other functional skincare needs, while the wider business also serves manufacturers and professional or medical channels with biomaterials and formulation inputs. This combination differentiates Bloomage Biotechnology from a narrowly focused cosmetics company: its identity is rooted in biotechnology and material science, with consumer products representing one part of a broader platform. Hyaluronic acid is central to the company’s public market identity because it is used in cosmetics, injectable and other medical applications, and industrial or formulation contexts. The company’s activities therefore connect upstream research and ingredient production with downstream product development. Its portfolio may include different molecular specifications and application formats, although the exact range and current commercial status of individual products should be verified against company disclosures. Bloomage Biotechnology is based in Jinan, Shandong, China, and operates in the Chinese market while presenting its products and capabilities to international customers. The company is publicly listed in China under ticker 688363.SH. Its public-facing corporate positioning emphasizes biotechnology, bioactive materials, product innovation, and the conversion of scientific capabilities into consumer and professional offerings. The available reference material does not provide a sufficiently detailed chronology of the company’s founding, leadership changes, financial performance, major campaigns, acquisitions, regulatory events, or product-launch dates. Those fields are therefore left unverified rather than supplemented with unsupported claims. The company should be distinguished from unrelated brands or organizations that use similar transliterations of “Bloomage.”

The available reference material identifies Bloomage Biotechnology as a Chinese biotechnology and beauty enterprise centered on hyaluronic acid and related bioactive applications, but it does not supply a reliable, detailed corporate history. The company is associated with Jinan in Shandong Province and operates across several connected layers of the value chain: research and development, production of bioactive ingredients, finished functional skincare, and medical or professional products. This structure is important to understanding the company’s identity. Rather than operating solely as a cosmetics label, Bloomage Biotechnology combines an upstream biotechnology and materials business with downstream consumer brands. Hyaluronic acid forms the most visible common thread across these activities, serving as a functional ingredient in skincare and as a material used in selected medical applications. The company’s consumer-facing portfolio includes Biohyalux, QuadHA, and Medrepair, while its broader business also addresses business customers seeking bioactive materials or formulation inputs. Bloomage Biotechnology is publicly traded in China under ticker 688363.SH. Its public positioning emphasizes scientific research, biotechnology, bioactive materials, and the development of products for beauty and healthcare-related use. The company’s activities are primarily connected with China, while its corporate website also presents an international orientation through its ingredient and product businesses. The supplied sources do not establish a verified founding year, founder, detailed sequence of corporate reorganizations, executive history, product-launch chronology, campaign record, or major transaction history. No such details are added here. A fuller historical entry would require company annual reports, exchange filings, official investor-relations materials, or authoritative independent reporting.

• Public listing

  [1]Bloomage Biotechnology official websitebloomagebioactive.com

  Bloomage Biotechnology is listed in China under ticker 688363.SH. The available material does not provide a verified listing date in the supplied sources.

Science-led Chinese biotechnology and beauty group combining bioactive-ingredient production with functional skincare and medical applications.

• Biotechnology ingredients

  Hyaluronic acid and bioactive raw materials

  The company is associated with the research, development, and production of hyaluronic-acid-related and other bioactive ingredients. These materials support applications in cosmetics, skincare, and medical or professional products. The precise specifications, grades, manufacturing sites, and current catalog are not established by the supplied reference material.

• Functional skincare

  Biohyalux

  Biohyalux is identified in the existing dossier as one of Bloomage Biotechnology’s consumer-facing skincare brands. It is associated with hyaluronic-acid-centered hydration and functional skincare positioning. Specific product families, launch dates, distribution scope, and current status are not verified in the supplied sources.

• Functional skincare

  QuadHA

  QuadHA is listed among the company’s flagship consumer offerings. The brand is positioned within functional skincare, with its name and corporate context linking it to hyaluronic-acid-related product development. Detailed formulas, hero products, markets, and launch chronology are not available in the supplied reference material.

• Functional skincare

  Medrepair

  Medrepair is identified as a Bloomage Biotechnology consumer skincare offering associated with repair-oriented and functional-care positioning. The supplied material does not establish its full product range, launch date, or current distribution.

• Medical and healthcare applications

  Medical and professional-use products

  Bloomage Biotechnology is also associated with medical or professional-use products based on the existing dossier. These activities extend the company beyond consumer skincare into healthcare-related applications of biomaterials and bioactive technologies. Product names, regulatory classifications, indications, and markets are not specified in the supplied sources.

• 2021

  Efficacy marketing of Bloomage Biotech's hyaluronic acid drinking water questioned, drawing consumer council attention

  In 2021, after Bloomage Biotech launched hyaluronic acid drinking water, its marketing of effects such as beauty and hydration was questioned by media and professionals. In 2023, the Shanghai Consumer Council further focused on evidence and advertising issues around oral hyaluronic acid, naming products such as Shuijiquan. The cited reports did not prove that ordinary foods can achieve medical aesthetics effects, nor did they provide a final illegal ruling against the product.

  Source

• 2020

  Shanghai Stock Exchange questions Huaxi Bio acquisition

  The Shanghai Stock Exchange sent Huaxi Bio an inquiry on September 29 about questions concerning its acquisition transaction, including the substantial difference between the target's valuations and reported financial figures. The article reports questions from the exchange, not a finding of wrongdoing.

  Source

Read more

• Unconfirmed

  Huaxi Biotech completes acquisition of Foist[7]华熙生物完成收购佛思特公司sc.stock.cnfol.com

  Huaxi Biotech reported that it had completed the arrangements for acquiring 100% of Dongying Foist Bioengineering Co., Ltd.

• 2020-09-29

  Shanghai Stock Exchange questions Huaxi Bio acquisition[6]Shanghai Stock Exchange questions Huaxi Bio acquisitionfinance.sina.com.cn

  Reported: 2020-09-30

  The Shanghai Stock Exchange sent Huaxi Bio an inquiry on September 29 about questions concerning its acquisition transaction, including the substantial difference between the target's valuations and reported financial figures. The article reports questions from the exchange, not a finding of wrongdoing.

• 2020-06-10

  Huaxi Bio announces acquisition of Fost Bio[8]华熙生物收购佛思特生物finance.sina.com.cn

  Reported: 2020-06-10

  Huaxi Bio announced its acquisition of Fost Bio. The article describes planned post-acquisition improvements to Fost Bio’s hyaluronic-acid production and says completion of the transaction would increase Huaxi Bio’s capacity and market share.

• 2019-10-23

  HuaxI Biologics wins China Patent Gold Award[9]华熙生物荣获中国专利金奖hy.stock.cnfol.com

  The State Intellectual Property Office announced the results of the 21st China Patent Awards, and Huaxi Biologics' technology for preparing oligomeric hyaluronate by enzymatic cleavage won the China Patent Gold Award.

1. 1Bloomage Biotechnology official websitebloomagebioactive.com
2. 2公司概况-华熙生物bloomagebioactive.com
3. 3产品-华熙生物bloomagebioactive.com
4. 4Efficacy marketing of Bloomage Biotech's hyaluronic acid drinking water questioned, drawing consumer council attentionthepaper.cn
5. 5Efficacy marketing of Bloomage Biotech's hyaluronic acid drinking water questioned, drawing consumer council attentionjiemian.com
6. 6Shanghai Stock Exchange questions Huaxi Bio acquisitionfinance.sina.com.cn
7. 7华熙生物完成收购佛思特公司sc.stock.cnfol.com
8. 8华熙生物收购佛思特生物finance.sina.com.cn
9. 9华熙生物荣获中国专利金奖hy.stock.cnfol.com